NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
Clinical Trials
48 trialsNCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT00490139 2025-03-21
ALTTO
Novartis
Phase 3 Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT00281658 2023-02-10
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
Novartis
Phase 3 Completed
NCT00444535 2021-10-25
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT00508274 2021-09-21
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Novartis
Phase 3 Terminated
NCT00553358 2021-09-21
Neo ALTTO
Novartis
Phase 3 Completed
NCT01808573 2021-06-11
NALA
Puma Biotechnology, Inc.
Phase 3 Completed
NCT00073528 2021-02-24
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT00820222 2019-04-02
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00320411 2019-01-31
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00477464 2018-09-17
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00536809 2017-12-18
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT00089999 2017-02-28
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00524303 2016-11-11
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
GlaxoSmithKline
Phase 2 Completed
NCT00829166 2016-10-31
EMILIA
Hoffmann-La Roche
Phase 3 Completed
NCT01328054 2016-06-08
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
GlaxoSmithKline
Phase 4 Completed
NCT00422903 2016-05-12
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT00320385 2016-02-26
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00387127 2015-06-25
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00075270 2015-05-06
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed
NCT01138046 2014-10-07
Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC
GlaxoSmithKline
Phase 2 Completed
NCT00374322 2014-08-18
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00356811 2014-07-21
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00424255 2014-07-18
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
GlaxoSmithKline
Phase 3 Completed
NCT00709618 2014-07-14
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
Phase 2 Terminated
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT00486954 2013-06-20
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00558103 2013-02-04
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01128543 2012-12-12
Lapatinib in Combination With Vinorelbine
GlaxoSmithKline
Phase 2 Completed
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00371566 2010-04-06
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed